Revisiting the cost-effectiveness of omalizumab. | Allergy;62(12): 1469, 2007 Dec. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Revisiting the cost-effectiveness of omalizumab.

Campbell, J D; Spackman, D E; Sullivan, S D.

Allergy ; 62(12): 1469, 2007 Dec.

Article in En | MEDLINE | ID: mdl-17983382

Subject(s)

Anti-Asthmatic Agents/economics; Antibodies, Monoclonal/economics; Asthma/drug therapy; Anti-Asthmatic Agents/therapeutic use; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal/therapeutic use; Antibodies, Monoclonal, Humanized; Asthma/economics; Cost-Benefit Analysis; Drug Costs; Humans; Models, Economic; Omalizumab

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Asthma / Anti-Asthmatic Agents / Antibodies, Monoclonal Type of study: Health_economic_evaluation Limits: Humans Language: En Journal: Allergy Year: 2007 Document type: Article

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Asthma / Anti-Asthmatic Agents / Antibodies, Monoclonal Type of study: Health_economic_evaluation Limits: Humans Language: En Journal: Allergy Year: 2007 Document type: Article